Also, the model - based approach
includes measures of uncertainty about our population estimates, which are not usually provided by more common approaches and are crucial for understanding the level of confidence we have about our estimates.»
Not exact matches
These risks and
uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products,
including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity
measures in European countries that may increase the amount
of discount required on Gilead's products; an increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products,
including Biktarvy; Gilead's ability to successfully commercialize its products,
including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and efficacy data from clinical studies may not warrant further development
of Gilead's product candidates,
including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
Based on the above conclusions, they consider that the future integrity
of the property is highly at risk, taking into account the possible prospect
of offshore oil exploitation, the
uncertainty about the impact
of invasive species, the already existing threats for which progress on the corrective
measures is unclear and the globally increasing effects
of climate change to coral reef systems,
including the Belize Barrier Reef system.
A comprehensive risk assessment would determine flood hazard for individual structures by modeling watershed and floodplain characteristics at fine spatial scales; it would describe the varying levels
of protection offered by all elements
of a flood protection system and mitigation
measures; and it would account explicitly for
uncertainties,
including those related to current and future flood hazard, structure value and vulnerability, and the current and future performance
of flood protection
measures.
Instead, they discuss new ways
of playing around with the aerosol judge factor needed to explain why 20th - century warming is about half
of the warming expected for increased in GHGs; and then expand their list
of fudge factors to
include smaller volcanos, stratospheric water vapor (published with no estimate
of uncertainty for the predicted change in Ts), transfer
of heat to the deeper ocean (where changes in heat content are hard to accurately
measure), etc..
3.3.2 In practice, there are many possible sources
of uncertainty in a measurement,
including: a) incomplete definition
of the measurand; b) imperfect reaIization
of the definition
of the measurand; c) nonrepresentative sampling — the sample
measured may not represent the defined measurand; d) inadequate knowledge
of the effects
of environmental conditions on the measurement or imperfect measurement
of environmental conditions; e) personal bias in reading analogue instruments; f) finite instrument resolution or discrimination threshold; g) inexact values
of measurement standards and reference materials; h) inexact values
of constants and other parameters obtained from external
These issues, which are either not recognized at all in the assessments or are understated,
include: - the identification
of a warm bias in nighttime minimum temperatures - poor siting
of the instrumentation to
measure temperatures - the influence
of trends in surface air water vapor content on temperature trends - the quantification
of uncertainties in the homogenization
of surface temperature data, and the influence
of land use / land cover change on surface temperature trends.
These findings are not sensitive to a wide range
of assumptions,
including the time series used to
measure temperature, the omission
of black carbon and stratospheric water vapor, and
uncertainty about anthropogenic sulfur emissions and its effect on radiative forcing (SI Appendix: Sections 2.4 — 7).
In fact, on Oct. 22, Morningstar raised its
uncertainty ratings, which
measure the margin
of safety around the fair value
of a stock, to high from medium for a number
of companies in the retail REIT universe,
including Kimco Realty Corp., Macerich Co. and PREIT, citing possible losses in revenue because
of consumer spending and the financing environment.